Nuvilex, Inc. Could Become Significant Player in the

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nuvilex, Inc. Could Become Significant Player in the Oncology Arena With Successful Phase III Trials

NEW YORK, NY--(Marketwired - May 22, 2013) - Nuvilex, Inc. ( OTCQB : NVLX ) is a diamond in the rough in the truest sense. Currently shares of the Silver Spring, Maryland, biotechnology firm can be purchased for around 0.15/share allowing investors to build an incredible position in the company for what could be a blockbuster future. Don't expect these great prices to last forever though. According to Nuvilex's COO, Dr. Gerry Crabtree, the company expects to start its pivotal Phase III trials in early 2014, so expect to start seeing news being released by the company as each piece of the trial starts to fall into place. Those who have any experience at all investing in biotech and pharmaceutical companies know the excitement generated as the news starts to unfold and the Phase III trials draw closer.

Many can probably remember the days when Dendreon Corp. lit up NASDAQ's boards with its first product, PROVENGE® (sipuleucel-T), a cancer drug approved by the U.S. Food and Drug Administration (FDA) in April 2010. By the end of the month, shares of Dendreon had reached almost $60.00/share which was a far cry from the $2.60 the company's shares hovered around while investors accumulated a position just one year prior to FDA approval.

No one is saying that Nuvilex is going to $60/share, but what could be said is the company is ideally priced for investors who are looking for that diamond in the rough, should the past be any indication of the future. If Nuvilex's Phase III trials in advanced, inoperable pancreatic cancer are successful, and we have every reason at this point to expect that they will be, then a host of potentials enter the picture for the future of the company. 

Stock House Group, a research and content development investment relations firm, contends that the Phase III trials for Nuvilex will be much like high school algebra where you knew the answer, but you still had to show your work. It is our opinion that Nuvilex's cell encapsulation technology is a "game-changer" and we feel the Phase III trials will confirm what the technology has already confirmed in two independent Phase II trials in advanced, inoperable pancreatic cancer.

In the data from those trials using encapsulated cells capable of converting the anticancer drug ifosfamide into its "cancer-killing" form, Median Survival Time and the One-Year Survival Rate were about doubled as compared to historical data for Gemzar -- the current standard and the only drug approved by the FDA as a single agent for the treatment of advanced, inoperable pancreatic cancer. Now, it's up to Nuvilex to "show its work" to the FDA and other regulatory agencies.

The list of potential accomplishments for Nuvilex is growing if the company does, in fact, have successful Phase III trials. And, if even one or two of those potential outcomes we've outlined below is realized, it could prove to be a real "boon" for Nuvilex shareholders.

Continue reading this Article at www.stockhousegroup.com/features .

About Stock House Group Stock House Group is a full service Investment Relations firm specializing in Research, Content Development and Awareness. The firm offers a platform for CEOs to tell their story through the press with Feature Articles, Research Reports, and CEO Interviews. At the same time, the company is building a library of Research for Investors to become better informed on small cap stocks.

Stock House Group www.stockhousegroup.com Email Contact (646) 397-4020

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 105

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 228

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 29

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 28

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
ICEYE Launches Gen5 SAR Satellite for Unrivaled Clarity

Updated Category News Views 60

Well, if you've been sleeping under a rock and missed the news, ICEYE just dropped another bombshell in the satellite biz. Gen5 is the name of the game, and it's claiming the spotlight for its razor-sharp imaging prowess. Now, we're talking about a satellite that supposedly snaps pictures with a resolution as fine as 11 cm. That's like spotting a flea on a dog's back from...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 47

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
2GenPen's Patent Push: Transforming Credit Analysis

Updated Category News Views 7

Changing the Game in Credit Analysis When you hear about a company snagging a patent, it's usually a big whoop-de-do; but 2GenPen's latest achievement is making some serious waves. This isn't some 'pat-yourself-on-the-back' sort of news – it's got teeth in the world of finance. These folks just locked down their second U.S. patent, number 12,784,096, and it's all about...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 131

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Innovation: Schneider Electric's Climate Tech Event

Updated Category News Views 170

Exploring the Excitement of the Climate Tech in the City Event The Climate Tech in the City event embodies the spirit of innovation, uniting key players in the climate technology sector. Leading organizations like Schneider Electric are at the forefront, showcasing groundbreaking advancements and sustainable practices. This year's gathering promises a vibrant day filled...

Continue Reading
Ouster Transforms Chattanooga into a Smart Traffic Hub

Updated Category News Views 404

Ouster's Groundbreaking Initiative in Smart Traffic Management In a significant development for urban traffic management, Ouster, Inc. (NASDAQ: OUST), recognized for its state-of-the-art lidar sensors, has launched a transformative project in Chattanooga. This venture stands out as the largest lidar-enabled traffic system in the United States, boasting a remarkable...

Continue Reading
Bicara Therapeutics Business Highlights and Q1 2025 Financial Review

Updated Category News Views 520

Bicara Therapeutics Announces Key Developments and Q1 2025 Financial Results Latest data from ongoing clinical trials to be showcased at upcoming conferences. Strong financial position enables sustained development through 2029. Bicara Therapeutics Inc. (Nasdaq: BCAX), a pioneering clinical-stage biopharmaceutical firm, focuses on delivering groundbreaking bifunctional...

Continue Reading
IO Biotech Gears Up for December Conferences: Insights and Highlights

Updated Category News Views 148

IO Biotech Prepares for Key Investor Conferences IO Biotech, a trailblazer in developing groundbreaking immune-modulatory cancer vaccines, is set to join two prominent investor events this December. The company, listed under NASDAQ: IOBT, is known for its innovative approach in the biopharmaceutical industry, particularly in creating off-the-shelf therapeutic cancer...

Continue Reading
Cardinal Energy Secures $40 Million Through Latest Debenture Offering

Updated Category News Views 267

Cardinal Energy Ltd. Announces a Major Offering Cardinal Energy Ltd. is excited to inform investors about its latest initiative aimed at raising funds through a significant offering. The company has entered into an agreement with a selected group of underwriters who will help facilitate the sale of $40 million in senior subordinated unsecured debentures. This strategic...

Continue Reading